Vivos Therapeutics (VVOS) Net Cash Flow Growth (3y) (2023 - 2026)
Vivos Therapeutics (VVOS) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.86 Bn | 176.56 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 128.65 Bn | 125.78 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 108.75 Bn | 99.53 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 68.34 Bn | 66.89 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 48.33 Bn | 44.65 Bn | 1.29 Bn | -87.88% |
| 6 | GE HealthCare Technologies | 28.35 Bn | 26.07 Bn | 1.98 Bn | -65.12% |
| 7 | Dexcom | 28.33 Bn | 27.21 Bn | 750.30 Mn | 129.29% |
| 8 | Smith & Nephew | 26.90 Bn | 26.32 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn | -48.90% |
| 10 | Vivos Therapeutics | 5.73 Mn | 3.62 Mn | 3.06 Mn | -70.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -70.45% |
| Dec 31, 2025 | 32.03% |
| Sep 30, 2025 | 38.92% |
| Jun 30, 2025 | -22.10% |
| Mar 31, 2025 | 14.17% |
| Dec 31, 2024 | 76.29% |
| Sep 30, 2024 | 53.75% |
| Jun 30, 2024 | -40.39% |
| Mar 31, 2024 | 30.71% |
| Dec 31, 2023 | -65.22% |
| Sep 30, 2023 | -66.30% |
| Jun 30, 2023 | -129.67% |
| Mar 31, 2023 | 127.19% |